Every 424B that Tempest Therapeutics Inc (TPST) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TPST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TPST filings page.
Tempest Therapeutics, Inc. (TPST) has filed a prospectus registering up to 8,910,579 shares of common stock for resale by Lincoln Park Capital Fund, LLC under a common stock purchase agreement. These shares consist of 560,356 Initial Commitment Shares, 350,223 Additional Commitment Shares, and up to 8,000,000 shares that Tempest may sell to Lincoln Park at its discretion.
Under the agreement, Lincoln Park has committed to purchase up to $50 million of TPST common stock over approximately 24 months from the Commencement Date, with an Initial Available Amount of $25 million that can automatically increase by an additional $25 million. Tempest will not receive proceeds from Lincoln Park’s resale of registered shares, only from its primary sales to Lincoln Park, which are priced off the market with specified discounts and volume caps.
As of August 19, 2026, Tempest had 16,539,767 shares outstanding, and a Nasdaq Capital Market closing price of $1.06 per share was recorded on August 28, 2026. The company warns that issuances under this facility may cause substantial dilution and that access to the full $50 million is constrained by a 3,195,881-share Exchange Cap, a 4.99% Beneficial Ownership Limitation, and Nasdaq stockholder-approval rules.
Tempest Therapeutics, Inc. registers for resale up to 2,426,897 shares of its common stock, consisting of 2,344,828 shares issuable upon exercise of newly issued warrants and 82,069 shares issuable upon exercise of placement agent warrants. The registration covers resale by the selling stockholders; the company will only receive proceeds if and when the Warrants are exercised for cash.
Tempest Therapeutics is registering 2,777,781 shares of common stock for resale by selling stockholders pursuant to registration rights granted in a March 20, 2026 private placement.
The registration covers (i) 462,964 issued shares, (ii) 925,927 shares issuable upon exercise of Series A Warrants, (iii) 925,927 shares issuable upon exercise of Series B Warrants, and (iv) 462,963 shares issuable upon exercise of Pre-Funded Warrants. The company will not receive proceeds from resale by the selling stockholders; the company will receive proceeds only from any cash exercise of the Common Warrants and nominal proceeds from cash exercise of the Pre-Funded Warrants. Shares outstanding were 14,344,034 as of March 30, 2026, and the Nasdaq closing price was $1.56 per share on April 8, 2026.
Tempest Therapeutics is registering for resale up to 8,268,495 shares of its common stock issued to sellers in the Asset Purchase Agreement. The registration covers shares issued in connection with the Acquisition and permits the named selling stockholders and their permitted transferees to offer or sell the Shares from time to time.
The prospectus states we will not receive any proceeds from resale by the selling stockholders. The percentage ownership calculations are based on 14,344,034 shares outstanding as of March 25, 2026. Sales may occur in public or private transactions, at prevailing market prices or negotiated prices.
Tempest Therapeutics, Inc. is registering 487,000 shares of common stock and 685,414 prefunded warrant shares in a $3.625-per-share offering. The company is selling the common shares and prefunded warrants to a single investor, with each prefunded warrant priced at $3.624 and exercisable for one share of common stock at an exercise price of $0.001.
Gross proceeds are approximately $4.25 million, with placement agent fees of about $255,000 and estimated net proceeds of roughly $3.8 million, which Tempest plans to use primarily for working capital and general corporate purposes. After this transaction, assuming full cash exercise of all prefunded warrants, the company illustrates 1,172,414 new shares at an as-adjusted net tangible book value of $1.80 per share, implying dilution of $1.825 per share to new investors.
In a concurrent private placement, Tempest is also issuing common warrants to purchase up to 1,172,414 additional shares at a $3.50 exercise price, exercisable immediately for 18 months after the effectiveness of a separate resale registration, though these warrants and their underlying shares are not being registered in this prospectus supplement.